Evaxion Biotech AS (EVAX)
3.72
-0.11
(-2.87%)
USD |
NASDAQ |
May 17, 16:00
3.72
0.00 (0.00%)
After-Hours: 20:00
Evaxion Biotech Research and Development Expense (Quarterly): 2.298M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.298M |
| September 30, 2023 | 2.83M |
| June 30, 2023 | 2.936M |
| March 31, 2023 | 3.852M |
| December 31, 2022 | 4.073M |
| September 30, 2022 | 4.068M |
| June 30, 2022 | 4.112M |
| March 31, 2022 | 4.804M |
| December 31, 2021 | 6.154M |
| Date | Value |
|---|---|
| September 30, 2021 | 4.417M |
| June 30, 2021 | 5.111M |
| March 31, 2021 | 3.893M |
| December 31, 2020 | 2.856M |
| September 30, 2020 | 2.966M |
| June 30, 2020 | 2.57M |
| March 31, 2020 | 2.51M |
| December 31, 2019 | 2.946M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.298M
Minimum
Dec 2023
6.154M
Maximum
Dec 2021
3.670M
Average
3.852M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| DBV Technologies SA | 21.40M |
| Ascendis Pharma A/S | 76.78M |
| Cellectis SA | 25.53M |
| Adaptimmune Therapeutics PLC | 35.21M |
| Akari Therapeutics PLC | -- |